AbCellera BiologicsABCL -3.27%56 Net Debt Paydown Yield % is -2.94% as of Jun. 30, 2026. GuruFocus rates ABCL with a GF Score™ of 56/100 and a GF Value™ of $5.62 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 1,163 Biotechnology companies, AbCellera Biologics ranks worse than 83.49% on this metric.
Net Debt Paydown Yield % is a metric that evaluates the total amount of debt a company has paid in relation to its market capitalization. It is a measure of a company's willingness and ability to reduce its debt.
As of today, AbCellera Biologics's Net Debt Paydown Yield % was -2.94%.
AbCellera Biologics (NAS:ABCL) Net Debt Paydown Yield % Explanation
Net Debt Paydown Yield % is the change in average of four quarters of company's total debt over a company's market cap. Assuming the total value of a company remains that same, shareholder value is increased as debt is reduced. In other words, it is a measure of the willingness and ability of a firm's management to pay down debt. Companies that have high debt paydown yields indicate that they are more aggressive with paying down debt.
In the calculation of Net Debt Paydown Yield %, we use the reductions of TTM average total debt one-year-ago and TTM average total debt at present, divided by its Market Cap.
AbCellera Biologics Net Debt Paydown Yield % Related Terms
AbCellera Biologics Net Debt Paydown Yield % Historical Data
* Premium members only.
The historical data trend for AbCellera Biologics's Net Debt Paydown Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AbCellera Biologics Net Debt Paydown Yield % Chart
ABCL vs AGIO, KOD, IMNM: Net Debt Paydown Yield % Comparison
For the Biotechnology subindustry, AbCellera Biologics's Net Debt Paydown Yield %, along with its competitors' market caps and Net Debt Paydown Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AbCellera Biologics Net Debt Paydown Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, AbCellera Biologics's Net Debt Paydown Yield % distribution charts can be found below:
* The bar in red indicates where AbCellera Biologics's Net Debt Paydown Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* All the data are calculated by TTM values. Note that if a companies is traded in several exchanges, then we calculate the company level data for Net Debt Paydown Yield % using the primary share class stock data. The calculation result in definition page is for demonstration purpose only, and it's showing the share class level data. Therefore, the numbers in the calculation may differ from elsewhere if the stock is not a primary share.
What does a Net Debt Paydown Yield % of -2.94% mean?
AbCellera Biologics (ABCL) has a Net Debt Paydown Yield % of -2.94% as of Jun. 30, 2026. Net Debt Paydown Yield is a metric that evaluates the total amount of debt a company has paid in relation to its market capitalization. This metric provides insight into a company's willingness and ability to reduce its debt using free cash flow. View historical data on AbCellera Biologics and its competitors. According to the industry distribution chart, AbCellera Biologics ranks #971 out of 1163 companies in the Biotechnology industry, placing it in the top 83.5%.
Is AbCellera Biologics' Net Debt Paydown Yield % too high?
AbCellera Biologics' current Net Debt Paydown Yield % is -2.94%. Based on the distribution chart, AbCellera Biologics ranks #971 out of 1163 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, AbCellera Biologics has a GF Score™ of 56/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does AbCellera Biologics' Net Debt Paydown Yield % compare to AGIO and KOD?
According to the Biotechnology industry distribution chart, AbCellera Biologics ranks #971 out of 1163 companies for Net Debt Paydown Yield %. This places AbCellera Biologics in the lower half of its industry. The industry median Net Debt Paydown Yield % is 0.04. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Debt Paydown Yield % for a Biotechnology company?
The median Net Debt Paydown Yield % among Biotechnology companies is 0.04, based on 1,163 companies in the industry. Companies in the top quartile (top 25%) have a Net Debt Paydown Yield % significantly above this median, while those in the bottom quartile fall well below. However, Net Debt Paydown Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Debt Paydown Yield % mean?
A high Net Debt Paydown Yield % can signal that a stock is expensive relative to its fundamentals. Net Debt Paydown Yield is a metric that evaluates the total amount of debt a company has paid in relation to its market capitalization. This metric provides insight into a company's willingness and ability to reduce its debt using free cash flow. View historical data on AbCellera Biologics and its competitors. For the Biotechnology industry, the median Net Debt Paydown Yield % is 0.04 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. AbCellera Biologics's current Net Debt Paydown Yield % is -2.94%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AbCellera Biologics stock overvalued right now?
Based on GuruFocus' analysis, AbCellera Biologics (ABCL) is currently considered Significantly Overvalued. The stock's GF Value™ is $5.62, compared to a current price of $7.85 — trading 39.7% above its estimated fair value. The current Net Debt Paydown Yield % is -2.94%. AbCellera Biologics' overall GF Score™ is 56/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Debt Paydown Yield % calculated?
Net Debt Paydown Yield % is calculated from a company's financial statements. For AbCellera Biologics (ABCL), the current Net Debt Paydown Yield % is -2.94% as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is AbCellera Biologics (ABCL) Overvalued in 2026?
Based on GuruFocus' analysis, AbCellera Biologics stock appears to be overvalued.
The current stock price of $7.85 is trading 39.7% above its estimated GF Value™ of $5.62.
GuruFocus considers AbCellera Biologics to be Significantly Overvalued.
Key valuation signals for ABCL:
Net Debt Paydown Yield %: -2.94%
GF Value™: $5.62 vs. price of $7.85 (39.7% above fair value)
No single metric tells the full story. See the ABCL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.
56GF Score
Get the complete analysis for ABCL
Net Debt Paydown Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ABCL has been successfully added to your 
